Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 1


Oral and Poster Abstracts Oral 627. Aggressive Lymphomas: Clinical and Epidemiological: Real World evidence for CAR-T Management I Biological, Lymphomas, Non-Hodgkin Lymphoma, Bispecific Antibody Therapy, Diseases, Therapies, Immunotherapy, Lymphoid Malignancies L. Elizabeth Budde1, Adam J. Olszewski, MD2, Sarit Assouline, MD3, Manali Kamdar4*,...

  • 123456 Profile photo of Madelyn

    Here is another combination of a CD3-CD20 BITE and polatuzumab in R/R aggressive B cell lymphoma. This phase I/II enrolled 63 patients to date with 24 having received prior CART. The ORR was 65%, CR 48% with similar rate seen in patients with prior CART. 21% had grade 3/4 neutropenia.